Suggestions
Deborah Kobewka
CEO BioPhorum
Deborah Kobewka is the Chief Executive Officer of BioPhorum, a collaborative organization focused on advancing the biopharmaceutical and medical device industries. She has over 30 years of experience in healthcare and life sciences, having held various senior roles both in the UK and internationally.
Professional Background
Kobewka began her career in the pharmaceutical industry with Schering Healthcare in 1984 and later joined IMS Health, where she held several management positions, including leading the market research business in Europe and serving as President for the Asia Pacific region. She has also operated her own consulting firm, DKK Associates, and worked with GBI Health to expand business operations in China and Brazil.12
Before joining BioPhorum, she was CEO of Evaluate Ltd., further solidifying her extensive background in the pharmaceutical sector. Her leadership at BioPhorum involves facilitating collaboration among industry leaders to enhance drug development processes and best practices.23
Education
Deborah holds a degree in Biochemistry from the University of Sussex and is an alumna of the London Business School, which complements her extensive practical experience with a strong academic foundation.13
Current Role
As CEO of BioPhorum, Kobewka is responsible for steering the organization towards its mission of fostering collaboration within the biopharmaceutical industry. Her role involves mobilizing experts to create innovative solutions that address industry challenges.24
Highlights
After nearly three years as CEO at Evaluate I am moving on. It has been my privilege to lead the company through an incredibly exciting period of growth and to work with such a fantastic team of people. During my tenure the business has doubled in size, secured reinvestment from its PE partner HG, and more recently entered an exciting new chapter through merging with MMIT. Evaluate is successful because it continues to focus relentlessly on providing the commercial intelligence that its customers need to improve their performance. And their performance is about improving Pharma R&D strategic decision making and in turn patient outcomes. I’m so proud to have led the very talented Evaluate team and wish them all the best as they combine with MMIT under the leadership of Mike Gallup. Thank you to HG and more recently Welsh Carson for their investment and tremendous support to these great businesses. #Evaluate #MMIT
